BRAF Targets in Melanoma, Softcover reprint of the original 1st ed. 2015 Biological Mechanisms, Resistance, and Drug Discovery Cancer Drug Discovery and Development Series, Vol. 82
Coordonnateur : Sullivan Ryan J.
1. Melanoma: Historical Context
Suraj Venna, Sekwon Jang, Michael Atkins
2. Melanoma Pathogenesis
Jennifer A. Lo, David E. Fisher
3. Molecular Diagnostics and Tumor Mutational Analysis
Melissa A. Wilson and Katherine L. Nathanson
4. Clinical Utility of BRAF-targeted therapy in Melanoma
Jeffrey A. Sosman and Douglas B. Johnson
5. The Ethics of Randomized Trials in Oncology
Pallavi Kumar, Ryan J. Sullivan
6. Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma
Michael A. Davies
7. Targeting the cell cycle and p53 in combination with BRAF-directed therapy
Dale Han, Keiran SM Smalley
8. Combination BRAF-directed therapy and immunotherapy
Zachary A. Cooper, Zain Ahmed, Jennifer A. Wargo
9. Moving Forward: Making BRAF-Targeted Therapy Better
Keith T Flaherty
Examines BRAF-directed targets in melanoma including molecular biology/signal transduction, molecular diagnostics, immunology, and next-generation analytics
Highlights and summarizes the unique biological mechanisms of how BRAF-inhibitors work and why they ultimately fail
Explores combinations of molecular targeted therapy and how molecular targeted therapy may interact with immune-based therapy
Includes supplementary material: sn.pub/extras
Date de parution : 09-2016
Ouvrage de 204 p.
15.5x23.5 cm
Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).
Prix indicatif 138,03 €
Ajouter au panierDate de parution : 11-2014
Ouvrage de 204 p.
15.5x23.5 cm
Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).
Prix indicatif 158,24 €
Ajouter au panierThèmes de BRAF Targets in Melanoma :
Mots-clés :
BRAF-inhibitors; Next-Gen Sequencing; immunotherapy; p53; vemurafenib